Inversago

News

Sales of its obesity therapies may be accelerating, but Novo Nordisk is showing no signs of pushing the brake pedal on investments in the category.

Oncology

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.